SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 2nd, 2021 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is entered into and effective as of March 9, 2021, by and between Alzamend Neuro, Inc., a Delaware corporation (the “Company”) and Digital Power Lending LLC, a California limited liability company (including its designees, successors and assigns, the “Purchaser”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 2nd, 2021 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 31, 2020, by and between ALZAMEND NEURO, INC., a Delaware corporation, with headquarters located at 3802 Spectrum Blvd., Suite #112C, Tampa, FL 33612 (the “Company”), and DPW HOLDINGS, INC., a Delaware corporation, with its address at 201 Shipyard Way, Suite E, Newport Beach, CA 92663 (the “Buyer”).
TRANSITION SERVICES CONSULTING AGREEMENTConsulting Agreement • April 2nd, 2021 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
This Consulting Agreement (the “Agreement”), dated as of December 31, 2018 with an effective date of February 1, 2019 (the “Effective Date”), is entered into by and between Alzamend Neuro, a Delaware corporation, having his headquarters 3802 Spectrum Boulevard, Suite 112C, Tampa, Florida 33612 and William B. Horne, an individual (the “Consultant”). This Agreement supersedes any prior oral or written agreements between the parties hereto related to the matters set forth herein.
STRICTLY CONFIDENTIAL Alzamend Neuro Inc.Lead Underwriting Agreement • April 2nd, 2021 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
